Gilead agreed to acquire Arcellx for $7.8 billion in cash plus a contingent payment structure, moving to full ownership of anitocabtagene autoleucel (anito‑cel), a BCMA‑directed CAR‑T therapy for multiple myeloma. The deal consolidates Gilead’s Kite‑era cell therapy assets and eliminates Arcellx’s profit‑share obligations, positioning Gilead to control commercialization and regulatory strategy ahead of an FDA decision. The acquisition reflects Gilead’s push to regain momentum in cell therapy after uneven performance in its existing portfolio and aims to put anito‑cel in direct competition with J&J/Legend’s Carvykti. Clinical data cited by both companies and the pending BLA underpins the transaction; analysts flagged the potential to reaccelerate Gilead’s cell‑therapy growth if the therapy secures approval and market uptake.